Clinical trials: NSCLC (non-small Cell Lung Cancer)
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
- Trial name
- NCT00230126
- Testing
- erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Stage IV Non-small Cell Lung Cancer
KN046 in Patients With Advanced Non-small Cell Lung Cancer
This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.
- Trial name
- NCT03838848
- Testing
- KN046, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Non-small Cell Lung Cancer
Special Drug Use-results Surveillance of Tabrecta Tablets
This study was an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance.
- Trial name
- NCT04575025
- Testing
- Tabrecta tablets
- Where
- 78 sites in Japan
- Volunteers
- 109 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer (NSCLC)
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
This is an open label, phase II study in which cetuximab with concurrent thoracic radiotherapy followed by consolidation chemotherapy with paclitaxel/carboplatin/cetuximab will be administered to subjects with locally advanced…
- Trial name
- NCT00492206
- Testing
- Cetuximab
- Where
- 31 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Advanced Nonsmall Cell Lung Cancer
Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib
Studying samples of blood in the laboratory from patients receiving erlotinib may help doctors learn more about the effects of erlotinib on hormone levels.
- Trial name
- NCT00602433
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Nasopharyngeal Cancers, Lung Cancer (NSCLC)
The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors
This project involves conducting integrated PET/MR or PET/CT imaging using a CAIX-targeted PET tracer (e.g., [68Ga]Ga-DOTA-CAIX peptide) in clinically diagnosed malignant tumor patients, aiming to achieve the following…
- Conditions
- Nasopharyngeal Cancers, Lung Cancer (NSCLC), Esophageal Cancer, Glioma
- Trial name
- NCT07890038
- Testing
- Specific PET Imaging Agent Targeting CAIX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lung Cancer
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing the development or recurrence of lung cancer in former heavy smokers.
- Trial name
- NCT00055978
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of California, Los Angeles
Lung Neoplasms
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
The purpose of this study is to help answer: Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical…
- Trial name
- NCT00356525
- Testing
- pemetrexed, gemcitabine, carboplatin
- Where
- 17 sites in United States, Brazil and 1 more
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Continuous treatment until progression or occurence of intolerable Adverse Event (AE) or end of trial. The end of trial is one year after the last patient has entered the study.
- Trial name
- NCT02514174
- Testing
- Afatinib
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00391274
- Testing
- pemetrexed, docetaxel
- Where
- 7 sites in China
- Volunteers
- 211 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, Carcinoma Breast
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of…
- Trial name
- NCT05603013
- Testing
- Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
- Trial name
- KYLIN-2 (NCT06574347)
- Testing
- Vebreltinib, Osimertinib, PLB1004
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Cancer, Non Small Cell Lung Cancer
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments using positron emission tomography (PET) imaging in 21 patients with Stage IIIB/IV or recurrent non-small cell lung cancer (NSCLC) and an…
- Trial name
- NCT00708448
- Testing
- PET Imaging, Erlotinib, Bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
Advanced Non-Small Cell Lung Cancer
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.
- Trial name
- NCT05504278
- Testing
- IBI351, Cetuximab, pemetrexed
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-Small Cell Lung Cancer, Adjuvant Therapy
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
This study aims to evaluate the real-world effectiveness and safety of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-such as osimertinib, aumolertinib, and furmonertinib-as adjuvant…
- Trial name
- NCT07686185
- Testing
- Third-generation EGFR-TKI
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Non Small Cell Lung Cancer
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT01031225
- Testing
- STA 9090
- Where
- 21 sites in United States
- Volunteers
- 113 people
- Sponsor
- Synta Pharmaceuticals Corp.
ALK-positive Non-small Cell Lung Cancer, Real World Study
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
This study was a multicenter, prospective, non-interventional clinical study that included first-line and late-line patients with advanced non-small cell lung cancer with ALK fusions treated with the third generation ALK-TKI…
- Trial name
- NCT06361589
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Non Small Cell Lung Cancer Metastatic
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
With the improvement of systemic therapeutic effect(especially in the population with driver gene mutation), the incidence of brain metastases had significantly increased.
- Trial name
- NCT03732482
- Testing
- Temozolomide capsules, radiotherapy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Taizhou Hospital
Advanced Non-small Cell Lung Cancer
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy.
- Trial name
- NCT05001724
- Testing
- KN046, Lenvatinib, Docetaxel
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.